Fiera Capital Corp lessened its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 6.5% during the fourth quarter, HoldingsChannel reports. The firm owned 375,692 shares of the company’s stock after selling 26,195 shares during the quarter. Fiera Capital Corp’s holdings in Zoetis were worth $47,270,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd increased its position in Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after purchasing an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Pincus Capital Management LP bought a new position in Zoetis in the 4th quarter valued at approximately $2,109,000. Finally, AE Wealth Management LLC boosted its position in Zoetis by 71.3% in the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock valued at $18,185,000 after buying an additional 60,167 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Down 0.8%
Shares of NYSE:ZTS opened at $78.80 on Tuesday. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $169.50. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The business’s 50-day moving average is $99.76 and its 200-day moving average is $115.24. The company has a market capitalization of $33.03 billion, a price-to-earnings ratio of 13.07, a P/E/G ratio of 1.24 and a beta of 0.75.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is 35.16%.
Key Headlines Impacting Zoetis
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis received UK approval for Lenivia (izenivetmab), a long-acting osteoarthritis pain therapy for dogs, which could support future product sales and help offset some legal-related negativity. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
- Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, Robbins Geller, the Schall Law Firm, Bronstein Gewirtz & Grossman, and DJS Law Group, issued repeated reminders about the pending securities class action and the July 27 lead-plaintiff deadline. ROSEN, A LONGSTANDING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
- Negative Sentiment: The class-action filings alleging securities-law violations and investor losses may increase legal costs, create headline risk, and keep pressure on Zoetis shares until more clarity emerges. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS
Analyst Upgrades and Downgrades
ZTS has been the topic of a number of research reports. Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Morgan Stanley restated an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Finally, Citigroup dropped their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $133.92.
Get Our Latest Research Report on ZTS
Insider Activity
In related news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 11,650 shares of company stock worth $886,384 in the last quarter. 0.22% of the stock is owned by corporate insiders.
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Stories
- Five stocks we like better than Zoetis
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
